How much funding has Visterra raised?

Visterra has raised $116.1M in total funding, most recently a Series C round.

Who are Visterra's investors?

Visterra's investors include Polaris Partners, Vertex Venture Holdings, Bill & Melinda Gates Foundation, MRL Ventures Fund, Serum Institute of India, Temasek.

Where is Visterra headquartered?

Visterra is headquartered in Cambridge, Massachusetts, United States.

What industry is Visterra in?

Visterra operates in Biotech, Healthcare.

Visterra

Bringing better biologics to life.

Cambridge, United States · Founded 2007 · $116.1M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2007
Business Model: B2B

Website: visterra.com
Total Funding: $116.1M
Last Round: $23.6M Series COct 2017
Rounds: 7

About

Visterra is a biologics research and early-stage clinical development company focused on developing novel therapeutics for patients with immune-mediated and other hard-to-treat diseases. The company applies cutting-edge computational, AI, and experimental research methods alongside agile preclinical development to engineer next-generation antibody-based therapies. Visterra's lead program, sibeprenlimab (VIS171), targets IgA nephropathy (IgAN) and has received FDA acceptance and Priority Review designation. The company leverages a unique platform combining structural biology, computational design, and proprietary antibody engineering to develop differentiated biologics. Originally spun out of MIT, Visterra was founded in 2007 and is based in Cambridge, Massachusetts. The company was acquired by Otsuka Holdings, which continues to advance its clinical pipeline.

Summary

Visterra is a Biotech company based in Cambridge, United States, founded in 2007. It has raised $116.1M in total across 7 rounds, most recently a $23.6M Series C round in Oct 2017. Investors include Polaris Partners, Vertex Venture Holdings and Bill & Melinda Gates Foundation.